Method for the early detection of vomit behaviour in patients with eating disorders

The use of specific oral microbiota bacteria as biomarkers in saliva samples addresses the lack of effective markers for detecting vomiting behavior in eating disorders, offering a non-invasive and effective method for early detection and monitoring.

WO2024245802A1PCT designated stage expired Publication Date: 2024-12-05CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED MP (CIBER) +4
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2024/063842
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-26
Filing Date
2024-05-20
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current methods lack effective biological markers for early detection of vomiting behavior in patients with eating disorders, relying heavily on self-reported data and showing limited success in identifying oral and pharyngeal symptoms.

Method used

Utilizing the oral microbiota, specifically bacteria such as Granulicatella, Actinomyces, Bulleidia, Veillonella, and other genera, as biomarkers in saliva samples to detect and monitor vomiting behavior in patients with eating disorders through non-invasive sampling and PCR-based analysis.

Benefits of technology

The method demonstrates significant differences in oral microbiota profiles between patients with and without vomiting behavior, providing a novel approach for early detection, diagnosis, and monitoring of purging behavior in eating disorder patients, complementing traditional self-reported methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000012_0001
    Figure IMGF000012_0001
  • Figure IMGF000012_0002
    Figure IMGF000012_0002
  • Figure IMGF000013_0001
    Figure IMGF000013_0001
Patent Text Reader

Abstract

The present invention refers to the use of bacteria present in the oral microbiota of a patient with Eating Disorders (EDs) as diagnostic marker of the presence of vomiting behaviour in the patient. Specifically, the bacteria belong to one or more genera selected from Granulicatella and Actinomyces, and, optionally Bulleidia, Veillonella, Oribacterium, Porphyromonas, Gemella, Campylobacter and Aggregatibacter. Further, the present invention refers to the method for the detection of vomiting behaviour in a patient with EDs, comprising the steps of i) obtaining a saliva sample from the patient, ii) determining the bacteria profile of the saliva sample and comparing to the bacteria profile of a control sample, and iii) detecting whether there are statistically significant differences between both bacteria profiles, attributing such statistically significant differences to a vomiting behaviour. Finally, the invention refers to an in vitro kit adapted to implement the method of the invention.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] METHOD FOR THE EARLY DETECTION OF VOMIT BEHAVIOUR IN PATIENTS WITH EATING DISORDERS

[0002] DESCRIPTION

[0003] Field of the invention

[0004] The present invention relates generally to the Health Sector, in particular, to Eating Disorders (EDs). Specifically, the invention relates to a method for detecting the vomit behavior in patients with EDs based on the use of the oral microbiota as biomarker.

[0005] Background of the invention

[0006] Eating disorders (EDs) are serious psychological illnesses that are associated with severe disturbances in people’s eating behaviours. Preoccupation with food, body weight and shape are signals of these disorders. Due to these alterations, significant physical illnesses can be triggered and, in extreme cases, they can even cause death (the most frequent causes being suicide or malnutrition).

[0007] In Spain, recent studies point out a prevalence rate of eating disorders in the adolescent population, between 12 and 21 years old, of around 4.1-4.5%. Specifically, Anorexia Nervosa is around 0.3%, Bulimia Nervosa 0.8% and OSFEDs (other specific eating disorders, which include: atypical anorexia, purging disorder, subthreshold bulimic, binge eating disorder and night eating disorder) around 3.1 % of the female population aged 12-21. Except for patients with restrictive Anorexia Nervosa and patients with Binge Eating Disorder, EDs patients, specifically those with bulimic / purgative Anorexia Nervosa, Bulimia Nervosa and OSFED, present vomiting behaviour, consistent with ingestion, as a form of compensation and / or weight control. These patients would represent 70% of the total cases that attend to a specialized Unit for an eating problem.

[0008] As the only way to detect this vomiting behaviour, and therefore to adequately diagnose these patients, up to now only self-reported behaviour by the patient and / or their relatives has been used. With the exception of the consequent hypokalemia, in severe and / or long-lasting cases of the disorder, there is no biological marker that allows identifying the presence of vomiting in these patients. In the state of the art, various studies have been carried out aimed at assessing oral complications in patients with eating disorders and vomiting behaviour. From those studies, it can be deduced that these patients present a variety of oral and pharyngeal symptoms and signs, including dental caries and erosion, dental pain, increased level of cariogenic bacteria, xerostomia, decreased salivary pH, etc (Bretz, Walter et al. (2002). Oral profiles of bulimic women: Diagnosis and management. What is the evidence?. The journal of evidence-based dental practice. 2. 267-272. 10. 1067 / med.2002. 130222).

[0009] Likewise, it has been suggested that patients with Bulimia Nervosa (BN) may harbour a high proportion of aciduric organisms in their saliva due to acid regurgitation. In particular, information is collected on the higher prevalence of salivary microbes, particularly Streptococcus (S.) mutans, S. sobrinus, lactobacilli and yeasts, in patients with BN, compared to those without BN (Bretz WA, et al. “Salivary levels of putative cariogenic organisms in patients with eating disorders". Oral Microbiol Immunol. 1989; 4:230-232. [PubMed: 2640318]; Romanos, G. E., et al (2012). Oro-facial manifestations in patients with eating disorders. Appetite, 59(2), 499-504).

[0010] In the article by Dynesen, Anja et al. “Oral Findings in Anorexia Nervosa and Bulimia Nervosa with Special Reference to Salivary Changes", Oral Biosci Med. 2004. 1:1 SI- 169, different salivary findings are discussed as oral biomarkers of anorexia and bulimia. In addition to the clinical finding of enlargement of the salivary glands, mainly the parotid glands, an elevated salivary level of Streptococcus sobrinus is suggested again as a biomarker of bulimia.

[0011] However, no conclusive results have been obtained so far, making it clear that more research is needed to describe these or any other differences in the oral microflora of people with anorexia and bulimia, compared to healthy controls, to identify oral markers that allow the development of an effective method for the early detection of vomiting and monitoring of these patients.

[0012] Summary of the invention

[0013] In a first aspect, the present invention refers to the use of the bacteria present in the oral microbiota of a patient with Eating Disorders (EDs) as diagnostic marker of the presence of vomiting behaviour in the patient.

[0014] In a second aspect, the present invention refers to a method for the detection of vomiting behaviour in a patient with EDs comprising the use of bacteria present in the oral microbiota of a saliva sample from the patient as a marker of said behaviour.

[0015] In a third aspect, the invention refers to an in vitro kit including one or more primer pairs able to amplify the bacteria belonging to a genus selected from the group consisting of Granulicatella, Actinomyces, and its combination and, optionally, a genus selected from the group consisting of Porphyromonas, Gemella, Campylobacter, Aggregatibacter, Oribacterium, Bulleida, and Veillonella, and combinations thereof, adapted to implement the method of the invention.

[0016] Brief description of the drawings

[0017] Figure 1.- Bacteria found statistically significant different between vomit and control groups at genus level (p<0.05). The abundance levels of the studied groups in both forms, filtered counts and logaritmically transformed counts, are shown for (A) Actinomyces, (B) Bulleidia, (C) Veillonella, (D) Oribacterium and (E) Granulicatella.

[0018] Figure 2.- Bacteria found statistically significant different between vomit and control groups at species level (p<0.05). The abundance levels of the studied groups in both forms, filtered counts and logaritmically transformed counts, are shown for (A) Actinomyces sp, (B) Veillonella rogosae and (C) Granulicatella elegans.

[0019] Figure 3.- Correlations between frequency of vomit and the relative abundance of genera found statistically significant. A) Correlation between relative abundance of Actinomyces and Granulicatella in patients’ samples with the times that the patients vomited. B) Correlation between the average of relative abundance of Actinomyces and Granulicatella and the whole population divided into CT (no vomit), patients who vomit once a day (1), twice a day (2) or 3 times or more a day (3).

[0020] Detailed description of the invention

[0021] In response to the lack of tools in the state of the art that allow early detection of the presence of self-induced vomiting in patients with Eating Disorders (EDs), the present invention shows the diagnostic and prognostic capacity of the oral microbiota to be used as a biomarker of purging behaviour in these patients.

[0022] Therefore, an object of the present invention is to be able to detect vomit behaviour in patients with EDs, at an early stage, using saliva samples, that can be collected non-invasively and simply.

[0023] To reach that objective, following a case-control design, the authors of the invention carried out clinical trials with saliva samples from patients diagnosed with EDs, who presented vomiting as a compensatory behaviour (anorexia nervosa purgative subtype, bulimia nervosa or another specified eating disorder), and they were compared with samples from a group of control participants without EDs or purging behaviour.

[0024] Saliva samples were analyzed in the laboratory of the Biomedical Research Institute of Malaga (I Bl MA) with specific reagents for the determination and identification of biomarkers in oral microbiota.

[0025] According to the information obtained, the authors of the present invention have been able to conclude the following:

[0026] The bacteria population in saliva of control participants differs very highly significantly from the bacteria population of patients with vomiting behaviour (P<0.001).

[0027] According to the differential analysis of both groups at genus level, as well as the correlation analysis, patients with vomiting behaviour have an increased abundance levels of Actinomyces and Granulicatella than control participants, determining a positive correlation between Granulicatella and Actinomyces and the frequency of vomiting.

[0028] According to the differential analysis of both groups at genus level, patients with vomiting behaviour have a lower amount of Veillonella and an increased amount of Bulleidia than control participants.

[0029] According to the presence or absence of the different bacteria found at genus level in the saliva microbiota profile, the presence of vomiting behaviour is related to the presence of the genera Porphyromonas, Gemella, Campylobacter, Aggregatibacter and Oribacterium, independent of their abundance levels.

[0030] These findings show the great potential of the oral microbiota in the development of programs to identify self-induced vomiting in patients with EDs and to observe the frequency of this vomit behaviour. In particular, these results support the use of these specific bacteria as novel biomarkers for detection, diagnosis, monitoring and prediction of vomiting behaviour in patients with EDs, being able to complement the classical tools used up to now, mainly based on patients’ self-reported behaviour.

[0031] Based on the above, in a first aspect, the present invention refers to the use of the bacteria present in the oral microbiota as early diagnostic marker of the presence of vomiting in patients with EDs.

[0032] In the context of the present invention, the term "oral microbiota" refers to the set of different microbial communities whose development, maturation and control are modulated by a wide range of environmental conditions. Although the oral cavity is continuously subjected to environmental stressors, the oral microbiome remains relatively stable over time in healthy people. Changes in the profile of the oral microbiome can provide information about the onset, progression, and recurrence of the disease. Furthermore, the oral microbiome provides an excellent source for biomarker discovery due to low inter- and intra-biological variations.

[0033] The present invention provides with specific biomarkers in the oral microbiota that allow an early detection of vomiting behaviour, in patients with eating disorders, and its severity.

[0034] In a particular embodiment, the invention refers to the use of bacteria of one or more genera selected from the group consisting of Granulicatella and Actinomyces, in a saliva sample, as early diagnostic marker of vomiting behaviour in patients with EDs. In a preferred embodiment, those bacteria are used in combination with bacteria of one or more genera selected from the group consisting of Bulleidia, Veillonella, Oribacterium, Porphyromonas, Gemella, Campylobacter and Aggregatibacter.

[0035] In a second aspect, the present invention refers to a method for the detection of vomiting behaviour in a patient with EDs comprising the use of bacteria present in the oral microbiota of a saliva sample from the patient as a marker of said behaviour (method of the invention).

[0036] To identify specific markers in oral microbiota the following steps can be followed: i) Obtaining a saliva sample from the patient, ii) Determining the bacteria profile of the saliva sample and comparing to the bacteria profile of a control sample, and iii) Determining whether there are statistically significant differences between both bacteria profiles, attributing such significant differences to a vomiting behaviour.

[0037] Saliva is a slightly alkaline secretion of water, mucin, protein, salts, and often a starch- splitting enzyme (as ptyalin) that is secreted into the mouth by salivary glands, lubricates ingested food, and often begins the breakdown of starches. Saliva is released by the submandibular gland, parotid gland, and / or sublingual glands and may be stimulated by the sympathetic and / or parasympathetic nervous system activity. Saliva released primarily by sympathetic or parasympathetic induction may be used to isolate microRNAs.

[0038] The advantages of saliva as a diagnostic fluid are extraordinary since it is simple to collect, easy to store, non-invasive, and contains high-quality DNA. Saliva contains biomolecules, including DNA, mRNA, microRNA, proteins, metabolites, and microbiota; changes in the concentration of these biomolecules in saliva can be used to search for biomarkers and help identify diseases.

[0039] In the context of the present invention, saliva may be collected by expectoration, swabbing the mouth, passive drool, or by other methods known and widely used in the art. It can be collected from the mouth prior to or after a rinse. In some embodiments, a saliva sample may be further purified by centrifugation, filtration, or other means that preserves microbial RNAs.

[0040] In a preferred embodiment of the method of the invention, saliva samples are collected using two different simple, fast and non-invasive procedures (less than 5 minutes each): 1) saliva sample is collected (without straining the throat) in a sterile wide-mouthed bottle; or 2) saliva samples are collected by means of a swab from the posterior part of the dental surface of the palatal face and the lingual face of the teeth.

[0041] Variables that could influence the results and / or quality of the sample collected can be controlled. Therefore, proteins or enzymes that degrade microRNA may be removed, inactivated or neutralized in the saliva sample. However, in a preferred embodiment, the saliva sample obtained from the patient is processed as little as possible, and immediately frozen at -80°C until further analysis.

[0042] In a particular embodiment, the step ii) of the method of the invention comprises determining in the saliva sample the abundance levels of bacteria of one or more genera selected from the group consisting of Granulicatella and Actinomyces, wherein a statistically significant increase in the abundance levels of one or more of said bacteria genera (i.e. Actinomyces, Granulicatella or both) in the saliva sample of the patient compared to the abundance levels of these bacteria in a control sample, is an indication of vomiting behaviour.

[0043] For the purposes of the method of the invention, P-values <0.05 are considered to be indicative of “statistically significant differences (increase / decrease)”.

[0044] In a preferred embodiment, the step ii) of the method of the invention further comprises determining the presence or absence of bacteria of one or more genera selected from the group consisting of Porphyromonas, Gemella, Campylobacter, Aggregatibacter and Oribacterium, in the saliva sample from the patient, wherein the presence of one or more of said bacteria confirms the indication of vomiting behaviour.

[0045] In a more preferred embodiment, the step ii) of the method of the invention further comprises determining the abundance levels of bacteria of one or more genera selected from the group consisting of Bulleidia and Veillonella, in the saliva sample from the patient, wherein statistically significant increased levels of the genus Bulleidia and / or statistically significant decreased levels of the genus Veillonella, compared to the levels of these bacteria in a control sample, further confirms vomiting behaviour.

[0046] Methods for detecting the presence of bacteria or measuring bacteria abundance levels in biological samples are well known in the art.

[0047] In the method of the invention, “abundance levels” can be referred to absolute normalized sequences, percentages, concentrations, or other measurement depending on the method used. These methods can include, but are not limited to, PCR, Denaturing gradient gel electrophoresis (DGGE), culture, or Next Generation Sequencing (NGS).

[0048] In a particular embodiment, the levels of abundance of bacteria can be determined by an amplification reaction of a nucleic acid preparation derived from said sample using specific primers capable of amplifying one or more representative regions of those genera of bacteria used as biomarkers in the method of the present invention. The term "specific" implies that the primers comprise a nucleotide sequence totally complementary to the genes or gene fragments employed by the present invention. The representative sequences of each genus, and that serve to identify those bacteria belonging to said genus in a saliva sample, are widely known by the person skilled in the art.

[0049] Preferably, the method of the present invention uses specific PCR primers targeting the bacterial 16S ribosomal RNA gene. In this case, bacterial abundance levels are based on the quantification of the number of copies of the 16S rRNA gene - a conserved prokaryotic gene with hypervariable sequences that differ between species - present in the sample. In particular, any pair of primers covering at least the V3 or / and V4 rRNA region but preferring a wider amplitude. Particularly, the determination of bacteria abundance levels is built under the measurement of the V2- 4-8 and V3-6, 7-9 regions. The sequencing of the 16S ribosomal RNA permits the identification of the whole plethora of bacteria present in the sample, allowing to further determine the specific bacterial biomarkers of the present invention.

[0050] In another aspect, the invention refers to an in vitro kit including one or more primer pairs able to amplify the bacteria belonging to a genus selected from the group consisting of Granulicatella, Actinomyces, and its combination and, optionally, a genus selected from the group consisting of Porphyromonas, Gemella, Campylobacter, Aggregatibacter, Oribacterium, Bulleida, and Veillonella, and combinations thereof, adapted to implement the method of the invention.

[0051] In a particular embodiment, the in vitro kit is adapted to the method of the invention according to the following steps:

[0052] Contacting the sample to be analyzed with a reaction mixture containing one or more specific primers able to amplify bacteria belonging to the genus Granulicatella, Actinomyces or its combination,

[0053] Amplification by means of polymerase chain reaction, and

[0054] Identification of the products formed in the prior step, being such information an indication of the abundance levels of bacteria belonging to the genus Granulicatella and / or Actinomyces.

[0055] In a preferred embodiment, the in vitro kit of the invention further comprises one or more pair of primers able to amplify bacteria of the genus selected from the group consisting of Porphyromonas, Gemella, Campylobacter, Aggregatibacter, Oribacterium and combinations thereof.

[0056] In a more preferred embodiment, the in vitro kit further comprises one or more pairs of primers able to amplify bacteria of the genus selected from the group consisting of Bulleidia, Veillonella and its combination.

[0057] Finally, in another embodiment, the invention also refers to the in vitro use of the kit, as defined above, for the implementation of the method of the present invention.

[0058] The following examples are not intended to limit the present invention but are by way of illustration. EXAMPLES

[0059] Microbiota profiles of the saliva of ED patients with known vomiting behaviour and a control group without vomiting were analyzed. A total of 54 samples corresponding to 27 samples per group were included in the study.

[0060] DNA was extracted from saliva samples using the commercial QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany) and targeted sequencing of the 16S rRNA gene was performed using the Ion 16S Metagenomics kit (Thermofisher) with two sets of primers covering the V2-4-8 and V3-6, 7-9 regions of the 16S rRNA hypervariable region in bacteria. After that, sequencing libraries were prepared with the commercial Ion Plus Fragment Library kit (Thermo Fisher Scientific Inc., Waltham, MA, USA), an emulsion PCR and sequencing of the libraries were performed on an Ion 530 chip (Ion 530TM Chip Kit) using the Ion Chef System and a Torrent S5TM system, respectively (Ion 510™ / 520™ / 530™ Kit-Chef, Thermo Fisher Scientific).

[0061] The bioinformatic analysis of the sequences was carried out in two main platforms: the open program QIIME2 for the analysis of the diversity of the samples and the analysis platform of ThermoFisher Scientific Ion Reporter in its version for the analysis of the 16S rRNA sequences, for the construction of bacteria tables at the genus and species level of the samples analyzed. This platform uses the Qiime program for the analysis of raw sequences and as reference bases: Curated MicroSEQ® 16S Reference Library v2013.1 ; Curated Greengenes v13.5. The tables obtained at the genus and species level were subsequently processed for their differential analysis of the groups in the MicrobiomeAnalyst webtool. In particular, the DESeq2 method was used.

[0062] After the analysis of the oral microbiota profiles through the saliva of control cases and patients, with and without vomiting, by means of directed sequencing of the 16S rRNA gene using Ion Torrent technology and the Ion 16S Metagenomics kit (Thermofisher), the main results were the following:

[0063] The microbial population of the control patients differed very highly significantly from the microbial population of the vomiting patients (P<0.001).

[0064] The core microbiome (bacteria taxa found in 100% of the samples within each group) was established and, at genus level, it was found that:

[0065] Table 1. Core microbiome at the genus level of the saliva samples of vomiting and control patients. And, at species level, it was found that:

[0066] Table 2. Core microbiome at the species level of the saliva samples of vomiting and control patients. Regarding the differential analysis, it was found that at genus level there were statistically significant differences between control and vomit groups in the following bacteria:

[0067] Table 3. Results of DesSeq2 differential analysis between vomiting and control groups at genus level.

[0068] Log2FC: fold change logarithm; IfcSE: standard error value; FDR: False Discovery rate.

[0069] The genera Actinomyces, Bulleidia and Granulicatella showed a statistically significant higher abundance levels in the vomit group (log2FC positive), while Veillonella and Oribacterium showed lower abundances levels (log2FC negative) in comparison with the control group.

[0070] The abundance levels of the studied groups in both forms, filtered counts and logarithmically transformed counts, are shown in fig.1. Those genera that differ between the vomit and control groups are shown according to the differential abundance analysis done with DESeq2 method (p<0.05).

[0071] Observing the results, the abundance levels of genera Actinomyces and Bulleidia, as well as Granulicatella, were found increased in the vomit group with respect to the control group. On the other hand, Veillonella and Oribacterium were found decreased in the vomit group.

[0072] Regarding the differential analysis, it was found that, at the species level, there are statistically significant differences between the vomit and control groups in the following bacteria:

[0073] Table 4. Results of DesSeq2differential analysis between vomiting and control groups at species level.

[0074] Log2FC: fold change logarithm; IfcSE: standard error value; FDR: False Discovery rate.

[0075] Actinomyces sp. and Granulicatella elegans showed a significatively higher abundance in the vomit group (log2FC positive), while Veillonella rogosae showed a significatively lower abundance in comparison with the control group (log2FC negative).

[0076] In fig.2 species that differ in their abundance between the groups of the study according to the differential abundance analysis done with DESeq2 method (p<0.05) are shown. According to the above, it was detected that Actinomyces (Actinomyces sp.) and Granulicatella (G. elegans) were found significatively increased in the vomit group with respect to the control group, while Veillonella rogosae was found significatively decreased in the vomit group.

[0077] Correlations between the frequency of vomiting and the relative abundance of the genera of interest (percentage of bacteria genera of interest compared to the total number of bacteria in the sample) were also found statistically significant.

[0078] In fig.3A the relative abundance levels of Actinomyces and Granulicatella genera of the whole population were correlated with the times that the patients vomited. In fig.3B the whole population were divided into CT (no vomit), participants who vomit once a day (1), twice a day (2) or 3 times or more (3), and the average of their relative abundance levels were represented. These results showed a positive correlation between the vomit biomarkers Actinomyces and Granulicatella and the frequency of vomit. The higher number of vomits, the greater abundance of these biomarkers.

[0079] Conclusion

[0080] These results showed the great potential of the oral microbiota in the development of programs to identify self-induced vomiting in patients with EDs and to observe the frequency of this vomit behaviour. In particular, these findings support the greatest potential of Granulicatella and Actinomyces genera as biomarkers for the early detection and monitorization of vomit behaviour in patients with Eating Disorders.

Claims

CLAIMS1. Use of the bacteria present in the oral microbiota of a patient with Eating Disorders (EDs) as diagnostic marker of the presence of vomiting behaviour in the patient, wherein the bacteria belong to one or more genera selected from the group consisting of Granulicatella and Actinomyces.

2. The use according to claim 1 , in combination with one or more genera selected from the group consisting of Bulleidia, Veillonella, Oribacterium, Porphyromonas, Gemella, Campylobacter and Aggregatibacter.

3. A method for the detection of vomiting behaviour in a patient with EDs, comprising the following steps: i. obtaining a saliva sample from the patient, ii. determining the bacteria profile of the saliva sample and comparing to the bacteria profile of a control sample, and iii. determining whether there are statistically significant differences between both bacteria profiles, attributing such statistically significant differences to a vomiting behaviour, wherein step ii) comprises determining the levels of abundance of bacteria of one or more genera selected from the group consisting of Granulicatella and Actinomyces in the saliva sample obtained from the patient, wherein a statistically significant increase in the levels of abundance of one or more of said bacteria genera, in the saliva sample from the patient, compared to the levels of abundance of the same bacteria in the control sample is an indication of vomiting behaviour.

4. The method of claim 3, wherein step ii) further comprises determining the presence or absence of bacteria of one or more genera selected from the group consisting of Porphyromonas, Gemella, Campylobacter, Aggregatibacter and Oribacterium, in the saliva sample of the patient; wherein the presence of one or more of said bacteria confirms the indication of vomiting behaviour.

5. The method according to any one of claims 3 or 4, wherein step ii) further comprises determining the levels of abundance of bacteria of one or more genera selected from the group consisting of Bulleidia and Veillonella in the saliva sample of the patient; wherein a statistically significant increase of the abundance levels of the genus Bulleidia and / or a statistically significant decrease of the abundance levels of the genus Veillonella, compared to the abundance levels of these bacteria in the control sample, further confirms the indication of vomiting behaviour.

6. An in vitro use of a kit comprising one or more pairs of primers able to amplify bacteria belonging to a genus selected from Granulicatella, Actinomyces and its combination, for the implementation of the method of claim 3.

7. The in vitro use, according to claim 6, further comprising one or more pairs of primers able to amplify bacteria belonging to a genus selected from the group consisting of Porphyromonas, Gemella, Campylobacter, Aggregatibacter, Oribacterium and combinations thereof.

8. The in vitro use, according to claims 6 or 7, further comprising one or more pairs of primers able to amplify bacteria belonging to a genus selected from the group consisting of Bulleidia, Veillonella and its combination.

Citation Information

Patent Citations

  • Compositions And Methods Useful In Detecting And Diagnosing Multiple Sclerosis

    US20220333159A1

  • A method of diagnosing depression in a subject

    WO2021250285A1